Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRDF
Strong SellSinkerCardiff Oncology, Inc. · Healthcare · United States · $73M · Avg Vol: $769K/d
COMPANY DESCRIPTION
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer patients by targeting the PLK1 enzyme pathway. Its proprietary small molecule drug candidate (onvansertib) with a specific mechanism of action targets key cancer pathways, potentially addressing unmet needs in various solid and liquid tumors. Cardiff Oncology is a specialized oncology biotechnology firm advancing novel therapeutic candidates for difficult-to-treat cancers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4M | 0.5M | 0.7M | 0.6M | 15.4% | 0.5M | 0.3M | 0.3M | -33.2% |
| EPS | -0.89 | -0.93 | -0.95 | -0.69 | — | -0.60 | -0.56 | -0.60 | — |
| Shares | 44.7M | 44.7M | 66.5M | 68.3M | +52.9% | 77.8M | — | — | — |
| Debt | 2.7M | 2.1M | 1.5M | 0.8M | -32.6% | 0.5M | — | — | — |
| Equity | 106.3M | 69.7M | 82.9M | 45.4M | -24.7% | — | — | — | — |
| Op CF | -33.8M | -30.9M | -37.7M | -37.9M | — | -40.9M | — | — | — |
| Inv CF | 38.1M | 36.2M | 13.7M | 1.3M | — | — | — | — | — |
| Fin CF | 75.0K | 0 | 53.8M | 2.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRDF are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc.(you) | $73M | 6 | Strong Sell |
| CING | Cingulate Inc. | $77M | 7 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%